Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Bioorg Med Chem Lett. 2015 Apr 17;25(11):2331–2334. doi: 10.1016/j.bmcl.2015.04.021

Figure 5. Effects of PEHPC derivatives in myeloma cells.

Figure 5

RPMI-8226 cells were incubated for 48 hours in the presence or absence of lovastatin (20 μM, Lov), PEHPC (5 mM), PEPC (5 mM), or the N-oxides 6 and 7 (5 mM). A) Cells were lysed using RIPA buffer to generate whole cell lysate or with Triton X-114 to generate a detergent (membrane) fraction and immunoblot analysis was performed. The Rap1a antibody detects only unmodified protein. β-Tubulin was used as a loading control for whole cell lysate and calnexin was used as the loading control for the detergent fraction. * Denotes the PARP cleavage product while ** denotes the calnexin cleavage product. The gels are representative of two independent studies. B) Intracellular lambda light chain concentrations were determined via ELISA. Data are expressed as percentage of control (mean + SD, n=3). The * denotes p<0.05 per unpaired two-tailed t-test and compares treated cells to untreated control cells.